N-乙基-3-氨基苯磺酰胺 | 56445-08-0

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-3-氨基苯磺酰胺
• 中文别名: 3-氨基-n-乙基苯磺酰胺
• 英文名称: 3-amino-N-ethylbenzenesulfonamide
• CAS: 56445-08-0
• 化学式: C₈H₁₂N₂O₂S
• 分子量: 200.261
• InChiKey: PGCYKJPSIKCLNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  80.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2935009090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-Ethyl 3-Aminobenzenesulfonamide
Synonyms: 3-Amino-N-ethylbenzenesulfonamide

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-Ethyl 3-Aminobenzenesulfonamide
CAS number: 56445-08-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H12N2O2S
Molecular weight: 200.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基-3-氨基苯磺酰胺 以89%的产率得到3-[N'-(3,5-diaminopyrazol4-ylidene)hydrazino]-N-ethylbenzenesulfonamide
  参考文献：
  名称：

  Pyrazole compounds

  摘要：

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。

  公开号：

  US20030060453A1
• 作为产物：
  描述：

  N-乙基-3-硝基苯磺酰胺 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 25.0 ℃ 、3.0 MPa 条件下， 以88%的产率得到N-乙基-3-氨基苯磺酰胺
  参考文献：
  名称：

  Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

  摘要：

  Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. Focused libraries of novel compounds based on PI-083 chloronaphthoquinone and sulfonamide moieties were synthesized to gain a better understanding of the structure-activity relationship responsible for chymotrypsin-like proteasome inhibitory activity. This led to the demonstration that the chloronaphthoquinone and the sulfonamide moieties are critical for inhibitory activity. The pyridyl group in PI-083 can be replaced with other heterocyclic groups without significant loss of activity. Molecular modeling studies were also performed to explore the detailed interactions of PI-083 and its derivatives with the beta 5 and beta 6 subunits of the 20S proteasome. The refined model showed an H-bond interaction between the Asp-114 and the sulfonamide moiety of the PI-083 in the beta 6 subunit. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.038

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013096153A1

  公开（公告）日：2013-06-27

  The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代喹啉衍生物。具体而言，本发明涉及根据公式I的化合物：其中R，R1，R2，R3和R4按如下定义。本发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢有关的疾病，例如癌症，更具体地说是乳腺癌、结肠癌、前列腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗与之相关的疾病的方法。
• Design, synthesis and biological activity evaluation of novel 4-((1-cyclopropyl-3-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl) oxy) pyridine-2-yl) amino derivatives as potent transforming growth factor-β (TGF-β) type I receptor inhibitors
  作者：Bin Tan、Xiaomeng Zhang、Xu Quan、Guochuang Zheng、Xue Li、Liwen Zhao、Wei Li、Bo Li

  DOI：10.1016/j.bmcl.2020.127339

  日期：2020.8

  ol-4-yl) oxy) pyridine-2-yl) amino derivatives as ALK5 inhibitors. The optimization led to identification of potent and selective ALK5 inhibitors 12r. The compound 12r exhibited strong inhibitory activity both in vitro and in vivo, and pharmacokinetics study showed an oral bioavailability of 57.6%. Thus, compound 12r may provide as new therapeutic option as ALK5 TGF-βR1 inhibitor.

  TGF-βI型受体（也称为激活素样激酶5或ALK5）在纤维化疾病的发展以及肿瘤的侵袭和转移中也起着至关重要的作用。靶向ALK5的小抑制剂的开发已被证实是纤维化疾病和癌症的潜在治疗策略。在这里，我们开发了各种作为ALK5抑制剂的4-（（1-环丙基-3-（四氢-2 H-吡喃-4-基）-1 H-吡唑-4-基）氧基）吡啶-2-基）氨基衍生物。优化导致了有效和选择性ALK5抑制剂12r的鉴定。化合物12r在体外和体内均表现出强大的抑制活性和药代动力学研究显示，口服生物利用度为57.6％。因此，化合物12r可以作为ALK5TGF-βR1抑制剂提供新的治疗选择。
• An efficient and practical synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones
  作者：Xinrong Tian、Dominic P. Suarez、William Hoi Hong Li、Allison K. McSherry、Robert M. Sanchez、Michael L. Moore、Jeffrey M. Axten

  DOI：10.1016/j.tetlet.2019.151312

  日期：2019.12

  We describe an efficient synthesis of 2,4-substituted pyrido[4,3-d]pyrimidin-5(6H)-ones, which involves the acid-promoted cyclization of cyano enamine 15 to afford 2,4-bis-thiomethyl pyrido[4,3-d]pyrimidin-5(6H)-one 17 as a key intermediate. Selective displacement of the 4-methylthio group by a wide range of anilines followed by oxidation of the 2-methylthio group and subsquent substitution by amines

  我们描述了2,4-取代的吡啶并[4,3- d ]嘧啶-5（6 H）-ones的有效合成，其中涉及酸促成氰基烯胺15的环化反应，从而提供2,4-双-硫代甲基吡啶基并[4,3- d ]嘧啶-5（6 ħ） -酮17，为关键中间体。通过广泛的苯胺选择性置换4-甲硫基，然后氧化2-甲硫基并随后被胺取代，使得能够合成各种2,4-二取代的吡啶并[4,3- d ]嘧啶- 5（6 H）-个。
• Thiazole-4-carboxyamide derivatives
  申请人：Buettelmann Bernd

  公开号：US20060160857A1

  公开（公告）日：2006-07-20

  The present invention is concerned with novel thiazole 4-carboxyamide derivatives of the general formula (I) and with methods for the preparation thereof, which compounds are useful as metabotropic glutamate receptor antagonists: wherein R 1 to R 4 are as defined in the specification.

  本发明涉及一种新型噻唑-4-羧酰胺衍生物，其通式为（I），以及其制备方法，这些化合物可用作代谢型谷氨酸受体拮抗剂： 其中R1至R4如规范中所定义。
• [EN] PYRRAZOLO-PYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE PYRRAZOLO-PYRIMIDINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005123738A1

  公开（公告）日：2005-12-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5 and p are as defined in the description and claims as well as to pharmaceutically acceptable salts thereof per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.

  该发明涉及公式（I）中R1、R2、R3、R4、R5和p的化合物，其中这些参数在说明和权利要求中有定义，以及其药学上可接受的盐本身和作为药用活性物质，其制备方法，基于与该发明相符合的化合物的药物，以及它们的生产，以及在控制或预防上述疾病方面使用与该发明相符合的化合物，以及分别用于生产相应的药物。